Dear Supernus Stockholder, We are very pleased with our performance in 2023 as we continued to successfully transition from our mature brands and set the stage to.
DGAP-News: Immun .
DGAP-News: Immune Regulation Limited: Immune Regulation appoints New Chairman and builds out Senior Management Team with standout industry professionals in the US
vom 17.12.2020, 09:00 Uhr
Bild: pixabay.com
DGAP-News: Immune Regulation Limited / Key word(s): Personnel
Immune Regulation Limited: Immune Regulation appoints New Chairman and builds out Senior Management Team with standout industry professionals in the US
17.12.2020 / 09:00
The issuer is solely responsible for the content of this announcement.
Immune Regulation appoints New Chairman and builds out Senior Management Team with standout industry professionals in the US
(London UK, New Orleans US, 17 December, 2020) Immune Regulation Ltd, a US and UK based clinical stage biotechnology company announced today a series of appointments to build out the Board and leadership team that will work alongside Jonathan Rigby, Group CEO of Immune Regulation, in advancing the development of its fir
Immune Regulation Limited
Immune Regulation appoints New Chairman and builds out Senior Management Team with standout industry professionals in the US
DGAP-News: Immune Regulation Limited / Key word(s): Personnel
Immune Regulation Limited: Immune Regulation appoints New Chairman and builds out Senior Management Team with standout industry professionals in the US
17.12.2020 / 09:00
The issuer is solely responsible for the content of this announcement.
Immune Regulation appoints New Chairman and builds out Senior Management Team with standout industry professionals in the US
(London UK, New Orleans US, 17 December, 2020) Immune Regulation Ltd, a US and UK based clinical stage biotechnology company announced today a series of appointments to build out the Board and leadership team that will work alongside Jonathan Rigby, Group CEO of Immune Regulation, in advancing the development of its first-in-class immune resetting therapies for autoimmune and allergic diseases.
Search jobs 17-Dec-2020 Immune Regulation Appoints New Chairman and Builds Out Senior Management Team with Standout Industry Professionals in the US
LONDON, UK and NEW ORLEANS, US, December 17, 2020 / B3C newswire / Immune Regulation Ltd, a US and UK based clinical stage biotechnology company announced today a series of appointments to build out the Board and leadership team that will work alongside Jonathan Rigby, Group CEO of Immune Regulation, in advancing the development of its first-in-class immune resetting therapies for autoimmune and allergic diseases.
Veteran biotech executive
Peter Greenleaf has been appointed
Chairman of the Board of Directors. Peter currently serves as the CEO and member of the Board of Directors of autoimmune therapeutics company Aurinia, (NASDAQ; AUPH / TSX; AUP). Previously, Peter served as the CEO of Cerecor Inc. (Nasdaq; CERC), the CEO and Chairman of Sucampo Pharmaceuticals Inc. (NASDAQ; SCMP),